AEDG is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by HPLC area | Higher grades are also offered |
| Primary analytical method | Reversed-phase HPLC, UV detection | Frequently paired with mass spectrometry |
| Confirmatory technique | Electrospray mass spectrometry | Observed mass compared with theory |
| Storage temperature | Minus 20 degrees Celsius, dry powder | Sealed, desiccated, protected from light |
| Solution handling | Prepare fresh before use | Hydrolysis proceeds in aqueous media |
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
=== Contestants === 1st - Karl Fong, Bakery Owner from Hercules, California 2nd - Jessica Brockway, Bakery Owner from Seattle, Washington 3rd - Pete Tidwell, Bakery Owner from Provo, Utah 4th - Julie Montgomery, Pastry Instructor from Toronto, Canada 5th - Jocelyn Jung, Bakery Owner from San Diego, California 6th - Sheldon Taylor-Timothy, Home Baker from Toronto, Canada 7th - Brittany Lombardi, Pastry Cook from The Bronx, New York 8th - Jess Eddy, Bakery Owner from Hartland, Wisconsin
The newer drugs have a better bioavailability as they are not charged and have a non-ionic interaction to the S1 pocket. Rivaroxaban During the SAR development of rivaroxaban, researchers realized that adding a 5-chlorothiophene-2-carboxamide group to the oxazolidonine core could increase the potency by 200 fold, which had previously been too weak for medical use. In addition to this discovery, a clear preference for the (S)-configuration was confirmed. This compound had a promising pharmacokinetical profile and did not contain a highly basic amidine group, but that had previously been considered important for the interaction with the S1 pocket. These findings lead to extensive SAR (structure-activity relationship) researches. During the SAR testing, R1 was defined as the most important group for potency. Pyrrolidinone was the first R1 functional group to significantly increase the potency but further researches revealed even higher potency with a morpholinone group instead. Groups R2 and R3 had hydrogen or fluorine attached and it was quickly assessed that having hydrogen resulted in highest potency. Groups R2 and R3 were then substituted for various groups, which were all less potent than the hydrogen, so hydrogen was the final result. As the chlorothiophene moiety had an inadequate water solubility, substituting it with another group was attempted but was unsuccessful. The chlorothiophene moiety binds to Tyr-228 at the bottom of the S1 pocket, making it a key factor regarding binding to FXa. Rivaroxaban has both high affinity and good bioavailability.
In addition to mambalgins, at least three other peptides from three different taxa have been identified as interacting with ASICs: PcTx1, from the South American tarantula Psalmopoeus cambridgei; APETx2, from the sea anemone Anthopleura elegantissima; and MitTx, a heterodimer from the snake Micrurus tener tener. PcTx1 and APETx2, like mambalgins, are ASIC inhibitors, albeit with different subtype specificities; MitTx is an activator associated with causing pain in vivo. The four proteins have no detectable sequence similarity. The natural function of ASIC-inhibiting analgesic peptides is unclear, as all are produced by predator animals yet have no known toxic effects on the corresponding prey.
=== Chemotherapy metabolite === Cyclophosphamide and ifosfamide treatment results in the production of acrolein. Acrolein produced during cyclophosphamide treatment collects in the urinary bladder and if untreated can cause hemorrhagic cystitis.
Sources: en.wikipedia.org
Fever or pyrexia in humans is a symptom of an anti-infection defense mechanism that appears with body temperature exceeding the normal range caused by an increase in the body's temperature set point in the hypothalamus. There is no single agreed-upon upper limit for normal temperature: sources use values ranging between 37.2 and 38.3 °C (99.0 and 100.9 °F) in humans. The increase in set-point triggers increased muscle contractions and causes a feeling of cold or chills. This results in greater heat production and efforts to conserve heat. When the set-point temperature returns to normal, a person feels hot, becomes flushed, and may begin to sweat. Rarely a fever may trigger a febrile seizure, with this being more common in young children. Fevers do not typically go higher than 41 to 42 °C (106 to 108 °F). A fever can be caused by many medical conditions ranging from non-serious to life-threatening. This includes viral, bacterial, and parasitic infections—such as influenza, the common cold, meningitis, urinary tract infections, appendicitis, Lassa fever, COVID-19, and malaria. Non-infectious causes include vasculitis, deep vein thrombosis, connective tissue disease, side effects of medication or vaccination, and cancer. It differs from hyperthermia, in that hyperthermia is an increase in body temperature over the temperature set point, due to either too much heat production or not enough heat loss. Treatment to reduce fever is generally not required. Treatment of associated pain and inflammation, however, may be useful and help a person rest.
== Clinical significance == Tumorigenesis in mammary glands can be induced biochemically by abnormal expression level of circulating hormones or local ECM components, or from a mechanical change in the tension of mammary stroma. Under either of the two circumstances, mammary epithelial cells would grow out of control and eventually result in cancer. Almost all instances of breast cancer originate in the lobules or ducts of the mammary glands.
== Treatment == Metabolic myopathies have varying levels of symptoms, being most severe when developed during infancy. Those who do not develop a form of a metabolic myopathy until they are in their young adult or adult life tend to have more treatable symptoms that can be helped with a change in diet and exercise. It might be more accurate to say that metabolic myopathies described as adult-onset, it isn't necessarily that they didn't develop in infancy (they are inborn—from birth—errors of metabolism) but that they didn't display severe enough symptoms to warrant the attention of medical professionals until their adult years (severe symptoms such as rhabdomyolysis, fixed muscle weakness due to years of repetitive injury, or the de-conditioning of muscles from a more sedentary adult lifestyle which exacerbated symptoms). Due to the rare nature of these diseases, it is very common to be misdiagnosed, even misdiagnosed multiple times. Once a correct diagnosis has been made, in adult years, looking back symptoms were present since childhood, but either brushed-off as growing pains, laziness, or told that they just needed to exercise more. It is especially difficult to get a diagnosis when symptoms are dynamic (exercise-induced), such as in muscle glycogenoses. Sitting in a doctor's office (at rest) or doing movements that only last a few seconds (within the time limit of the phosphagen system) the patient wouldn't display any noticeable abnormalities (such as muscle fatigue, cramping, or breathlessness).
Sources: en.wikipedia.org
policy – the various forms, past and present, of the U.S. 'war on drugs'". Outside interests, including "racism, fear, economic interests, domestic and international politics, global trade, domestic protectionism, war, arms control initiatives, the Cold War, development aid, and various corporate agendas", significantly shaped the conventions. And certain individuals played an outsized role in forming the policies: "while in positions of power at opportune moments, their beliefs, morals, ambitions and single-minded determination enabled them to exert exceptional influence over the shape of the international drug control regime." The efforts of US drug control commissioner Harry Anslinger and his Canadian counterpart and policy ally, Charles Henry Ludovic Sharman, are particularly notable. While many scholars view the drug conventions as a US-engineered prohibitionist regime, others offer more nuanced analyses. Among them, John Collins finds that, though "a plurality of the policy literature maintains this narrative, the historiography has since moved on." He suggests that the conventions emerged from complex multilateral negotiations, "a triangulation between various state interests and blocs." Sebastien Scheerer finds that global drug policy "rests on a highly coercive consensus masterminded by ... the United States", yet the US relied on "other governments' prejudices, plans and interests" in drug prohibition; America may have to "share the credit (and blame)" with other parties.
== Gene expression == The CCND1 gene encodes the cyclin D1 protein. The human CCND1 gene is located on the long arm of chromosome 11 (band 11q13). It is 13,388 base pairs long, and translates into 295 amino acids. Cyclin D1 is expressed in all adult human tissues with the exception of cells derived from bone marrow stem cell lines (both lymphoid and myeloid).
=== Hypertension === Beta blockers are widely used for the treatment of hypertension. A 2014 Cochrane review found that in individuals with mild-to-moderate hypertension, non-selective beta blockers led to a reduction of 10/7 mmHg (systolic/diastolic) without increased rates of adverse events. At higher doses, it was found to increase the rate of adverse effects such as a reduction in heart rate, without a corresponding reduction in blood pressure. A 2017 Cochrane review on the use of beta blockers in hypertension found a modest reduction in cardiovascular disease but little to no change in mortality. It suggested that the effects of beta blockers are inferior to other anti-hypertensive medications.
The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in coronary arteries following balloon angioplasty. The sirolimus is formulated in a polymer coating that affords controlled release through the healing period following coronary intervention. Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. However, this kind of stent may also increase the risk of vascular thrombosis.
Sources: en.wikipedia.org
The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.
The dry powder is commonly kept at minus twenty degrees Celsius, desiccated and away from light. Solutions are generally prepared fresh because they break down faster than the solid form.
Tandem mass spectrometry or enzymatic peptide mapping can establish residue order. A single intact mass value indicates composition and molecular weight but not always the precise arrangement of residues.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.